RT Journal Article SR Electronic T1 Evolution of Pulmonary Function in a Cohort of Interstitial Lung Disease Patients Positive to Antisynthetase Antibodies (ASAB) JF The Journal of Rheumatology JO J Rheumatol FD The Journal of Rheumatology SP jrheum.181141 DO 10.3899/jrheum.181141 A1 Montserrat Ixchel González-Pérez A1 José Guillermo Mejía-Hurtado A1 Diana Isabel Pérez-Román A1 Ivette Buendía-Roldán A1 Mayra Mejía A1 Ramcés Falfán-Valencia A1 Heidegger N. Mateos Toledo A1 Jorge Rojas-Serrano YR 2019 UL http://www.jrheum.org/content/early/2019/06/11/jrheum.181141.abstract AB Objective To describe the evolution of the pulmonary function in patients with ILD, positive to at least one of the ASAB after medical treatment, and to compare whether the evolution of pulmonary function is associated with the type of ASAB. Methods Patients with ILD and positive to at least one of the ASAB: Jo1, PL7, PL12, Ej or Oj, were included. The clinical evolution, time until death or censoring, and improvement of lung disease were registered. Results 118 patients were included. Most of the patients had a high extent of ground glass opacities in high resolution chest tomography (HRCT) and low extent of fibrosis. In the final evaluation of pulmonary function, (median of follow-up: 749.5 days of follow-up), 67% of the patients had lung disease improvement. The improvement occurred within the first 6 months after initiating medical treatment, and then after, pulmonary function remained stable in most of the patients. A decrease of the extent of ground glass opacities was demonstrated in HRCT at follow up in those patients with pulmonary improvement. No differences were observed in the percentage of patients that achieved improvement between the ASAB groups, neither in survival. Conclusion Improvement of pulmonary function was observed in 67% of the patients, improvement was observed in all ASAB groups and occurred within the 6 months after initiating medical treatment.